Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds allergen or component thereof
Reexamination Certificate
2005-02-01
2005-02-01
Nolan, Patrick J. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds allergen or component thereof
C424S133100, C424S177100
Reexamination Certificate
active
06849259
ABSTRACT:
A pharmaceutical composition for treating allergy is described. The composition comprises as an active ingredient a recombinant polyclonal antibody or a mixture of different monoclonal antibodies capable of reacting with or binding to an allergen together with one or more pharmaceutically acceptable excipients. The composition may be used topically as a solution, dispersion, powder, or in the form of microspheres. The polyclonal antibody is preferably a recombinant polyclonal antibody produced by phage display technology. The pairing of specific immunoglobulin variable region light chain and heavy chain maintained from the original polyclonal immune response or selected by panning using the allergen in question is preferably maintained by bulk transfer of the pairs into an expression vector.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4740371 (1988-04-01), St. Remy et al.
patent: 5458135 (1995-10-01), Patton et al.
patent: 5670626 (1997-09-01), Chang
patent: 5789208 (1998-08-01), Sharon
patent: 5797392 (1998-08-01), Keldmann et al.
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: WO 9609085 (1996-03-01), None
patent: WO 9810776 (1998-03-01), None
Roitt et al. (Immunology, Harper and Row, Publishers, New York, 1989, pp. 5.5-5.6 and 3.8).*
Franco M. Piazza et al. “Immunotherapy of Respiratory Syncytial Virus Infection in Cotton Rats (Sigmodon fulviventer) Using IgG in a Small-Particle Aerosol”,The Journal of Infectious Diseases 1992;166; 1422-4.
David E. Bice et al. “Animal Models of Asthma: Potential Usefulness for Studying Health Effects of Inhaled Particled”,Inhalation Toxicology,12:829, 2000.
Jürgen Schwarze et al. “Antigen-specific Immunoglobulin-A Prevents Increased Airway Responsiveness and Lung Eosinophilia after Airway Challenge in Sensitized Mice”,Am J Repir Crit Care Med,vol. 158. pp 519-525, 1998.
Wayne R. Gombotz et al. “The Stabilization of a Human IgM Monoclonal Antibody with Poly (vinylpyrrolidone)”,Pharmaceutical Research,vol. 11, No. 5, 1994.
Alan R. Brown et al. “Chamber for testing metered-dose propellant-driven aerosols of immunologically relevant proteins”,Journal of Immunological Methods,176 (1994) 203-212.
Mehdi Paborji et al. “Chemical and Physical Stability of Chimeric L6, a Mouse-Human Monoclonal Antibody”,Pharmaceutical Research,vol. 11, No. 5, 1994.
Kazuo Maruyama et al. “Targetability of novel immunoliposomes modified with amphipathic poly (ethylene glycol) s conjugated at their distal terminals to monoclonal antibodies”,Biochimica et Biophysica Acta1234 (1995) 74-80.
Alan R. Brown “Propellant-Driven Aerosols of Ptoteins”,Acrosol Science and Technology24:45-56 (1996).
Visco et al., J. Immunol., 1996; 157:956-962.
De Lalla et al., Mol. Immunol., 1996; 33:1049-1058.
Urbanek et al., Clin. Allergy, 1986; 16:317-322.
Bousquet et al., J. Allergy Clin. Immunol., 1987; 79:947-954.
Drejer Kirsten
Haurum John S.
Morch Ulrik Gregers Winther
Bieker-Brady P.C. Kristina
Clark & Elbing LLP
Nolan Patrick J.
Symphogen A/S
LandOfFree
Polyclonal antibody composition for treating allergy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polyclonal antibody composition for treating allergy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyclonal antibody composition for treating allergy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3455797